Immune therapy for hepatitis B

Akbar, Sheikh Mohammad Fazle; Al‐Mahtab, Mamun; Khan, Md. Sakirul Islam; Raihan, Ruksana; Shrestha, Ananta

doi:10.21037/atm.2016.08.48

Cited by 4 publications

(1 citation statement)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 To overcome these immune defects, currently, several clinical trials based on reshaping host immune responses have been conducted. 18,19 In 1995, we conducted a pilot study on the use of HBsAg-HBIG (immune complex, IC of hepatitis B surface antigen complexed with high-titer immunoglobulin) to treat CHB patients. 20 Our hypothesis was, by complexing HBsAg with anti-HBs at an appropriate ratio, HBsAg can be more effectively delivered into host antigen presenting cells (APCs) via their Fc receptors, as being amply demonstrated in animal models.…”

Section: Introductionmentioning

confidence: 99%

Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

Zhou

Gong

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

An HBsAg-HBIG therapeutic vaccine (Yeast-derived Immune Complexes, YIC) for chronic hepatitis B (CHB) patients has undergone a series of clinical trials. The HBeAg sero-conversion rate of YIC varied from 21.9% to 14% depending on the immunization protocols from 6 to 12 injections. To analyze the immunological mechanisms exerted by 6 injections of YIC, 44 CHB patients were separately immunized with YIC, alum as adjuvant control or normal saline as blank control, with add on of antiviral drug Adefovir in all groups. Kinetic increase in Th1 and Th2 cells CD4 T cell sub-populations with association in decrease in Treg cells and increase of Tc1 and Tc17 cells in CD8 T cells were observed in YIC immunized group. No such changes were found in the other groups. By multifunctional analysis of cytokine profiles, significant increase of IL-2 levels was observed, both in CD4 and CD8 T cells in the YIC immunized group, accompanied by increase in IFN-gamma and decrease of inhibitory factors (IL-10, TGF-β and Foxp3) in CD4 T cells. In the alum immunized group, slight increase of IL-10, TGF-β and Foxp3 in CD4 T cells was found after the second injection, but decreased after more injections, suggesting that alum induced early inflammatory responses to a certain extent. Similar patterns of responses of IL-17A and TNF-α in CD8T cells were shown between YIC and the saline group. Results indicate that add on of Adefovir, did not affect host specific immune responses.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

Zhou

Gong

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Introduction to antiviral therapy

Dhara¹,

Nayak

2023

Viral Infections and Antiviral Therapies

View full text Add to dashboard Cite

Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes

Chu

Nguyen

et al. 2021

J Clin Microbiol

View full text Add to dashboard Cite

We developed a novel real-time PCR assay that simultaneously evaluates eleven major nucleos(t)ide antiviral (NA) drug-resistance mutations (mt) in chronic hepatitis B patients (CHB), including L180M, M204I/V, and V207M (lamivudine (LMV) resistance), N/H238A/T (Adefovir (ADF) resistance) which are circulating in Vietnam; T184G/L, S202I, M250V (entecavir (ETV) resistance), and A194T (tenofovir resistance) which have been recently reported in several studies across the globe. We detected drug-resistant mt in HBV samples using our predesigned panel of allele-specific locked-nucleic acid (LNA) probes. Our assay had a high sensitivity of 5% in a low HBV DNA population of ≥5 ×10 3 IU/mL and was validated in a cohort of 130 treatment-naive children and 98 NA-experienced adults with CHB. Single-point mt for LMV- and ADF-resistance were detected in 57.7% and 54.1% of the child and adult samples, respectively, with rtV207M (42.3%, children; 36.7%, adults) and rtN238T/A (15.4%, children; 16.3, adults) being the most frequent mt in these populations. Multiple-point mt including rtL180M-rtM204V- rtN238A and rtL180M-rtM204I were only identified in two children, resulting in LMV-ADF-resistance and reduced ETV susceptibility. In conclusion, this assay accurately identified the mt profile of children (98.4%) and adults (91.2%) with CHB, which is comparable to established methods. This fast and sensitive screening method can be used for the detection of major NA-resistant mt circulating in developing countries, as well as providing a model for the development of similar mt-detection assays, especially for use in non-hospitalised patients who need their results within half a day before starting treatment.

show abstract

Immune therapy for hepatitis B

Cited by 4 publications

References 84 publications

Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

Introduction to antiviral therapy

Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes

Contact Info

Product

Resources

About